<DOC>
	<DOCNO>NCT03076970</DOCNO>
	<brief_summary>This randomize , double-blind , three-period , cross-over study investigate effect sumatriptan ( Imitrex ) 100 mg pharmacodynamics pharmacokinetics lasmiditan 200 mg .</brief_summary>
	<brief_title>Effect Single Oral Doses Lasmiditan When Coadministered With Single Oral Doses Sumatriptan Healthy Subjects</brief_title>
	<detailed_description>This randomize , double-blind , three-period , cross-over study investigate effect single dos sumatriptan ( Imitrex ) 100 mg pharmacodynamics single dos lasmiditan 200 mg . The study last approximately 6 week include 3 week screen 22 day study . Screening conduct within approximately 21 day first dose study medication . Each dose period last 3 day ( Day 1 , Day 1 , Day 2 ) . A wash-out period 6 day take place dose . The End Study Visit ( EoS ) take place 5 ( +/- 2 ) day third dosing period complete .</detailed_description>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>1 . Male female age 1860 year , inclusive . 2 . Able willing give write informed consent . 3 . BMI 18 32 kg/m2 , inclusive . 4 . Subjects must able refrain consume xanthine , quinine caffeine containing beverage , must refrain prolonged intensive physical exercise study ( 72 hour prior dose last study visit ) . 5 . Women must : pregnant breastfeed plan become pregnant study 6 . All female must negative serum pregnancy test screen negative urine pregnancy test checkin Day 1 period . All woman must agree use adequate method contraception study 30 day follow endofstudy visit . 7 . Male subject must agree utilize highly effective method contraception ( condom plus spermicide ) heterosexual intercourse clinic admission 30 day follow end study visit . 8 . Male subject must agree refrain sperm donation clinic admission least 30 day follow end study visit . 9 . Subjects must able swallow multiple pill simultaneously . 10 . Subjects must able understand requirement study must willing comply requirement study . 1 . Any medical condition , clinical laboratory test reason judgment Investigator designee make subject unsuitable study . 2 . Any clinically significant abnormality ( determine Principal Investigator designee ) hematology , blood chemistry and/or urinalysis lab test screen Period 1 D1 . 3 . Known hypersensitivity lasmiditan , sumatriptan ( Imitrex ) , excipient lasmiditan sumatriptan ( Imitrex ) oral tablet . 4 . Use prescription medication , include MAOA inhibitor drug associate serotonin syndrome , within 14 day prior dose ( except hormonal contraceptive ) except 5HT1 ( serotonin ) agonists selective serotonin reuptake inhibitor . 5 . History , symptom , sign ischemic cardiac , cerebrovascular , peripheral vascular syndrome include limited angina pectoris , myocardial infarction , silent myocardial ischemia ( Ischemic cardiac syndrome ) , stroke , transient ischemic attack ( cerebrovascular syndrome ) , ischemic bowel disease ( peripheral vascular disease ) . 6 . History , symptom , sign vasospastic coronary artery disease . 7 . History , symptom , sign arrhythmia Wolff Parkinson White ( WPW ) syndrome could affect subject 's safety opinion Investigator designee . 8 . History , symptom , sign severe hepatic impairment . 9 . History , symptom , sign diabetes . 10 . History within previous 3 year current evidence abuse ( accord DSMIV criterion ) drug , prescription illicit , alcohol ; positive urine screen drug abuse breathalyzer alcohol test . 11 . Positive urinary test drug abuse and/or alcohol breath test Screening and/or checkin Day 1 Period . Cotinine include screen . 12 . History orthostatic hypotension without syncope . 13 . Supine systolic blood pressure ( BP ) &gt; 135 mm Hg , diastolic BP &gt; 85 mm Hg , respiratory rate &gt; 20 breath per minute , pulse &gt; 90 beat per minute , temperature &gt; 37.5ยบ Screening . Low value vital sign measurement assess discretion Investigator designee . For orthostatic vital sign , decrease systolic and/or diastolic blood pressure great 20 mmHg . Any change assess discretion Investigator designee . 14 . ECG change include QT interval prolongation congenital long QT syndrome . 15 . Electrolyte abnormality ( e.g. , hypokalemia hypomagnesemia ) , congestive heart failure , medicinal product lead QT prolongation . 16 . Any clinically significant alanine aminotransferase ( ALT ) , alkaline phosphatase ( AP ) , aspartate aminotransferase ( AST ) , bilirubin abnormality judge Investigator designee Screening . 17 . Treatment centrally active drug affect peripheral cholinergic transmission within 3 month study entry . 18 . Consumption grapefruit , grapefruit juice , Seville oranges , Seville orange juice , beverage contain juice consumption member mustard green family ( include kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard ( i.e . seed , green , spice condiment ) ) within 72 hour dose . 19 . Tobacco nicotine user except subject stop use tobacco nicotine 1 year signing informed consent . 20 . Subject imminent risk suicide suicide attempt within 6 month prior screen visit . 21 . Participation clinical trial experimental drug device previous 30 day . 22 . Positive Hepatitis C antibody , Hepatitis B surface antigen , positive human immunodeficiency virus ( HIV ) antibody . 23 . Subjects donate plasma 7 day blood 3 month precede study drug administration . 24 . Subjects inability communicate well Investigator designee study staff ( i.e. , language problem , poor mental development impair cerebral function ) . 25 . Inability fast consume food provide study . 26 . Relatives staff directly report Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>